We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples

By LabMedica International staff writers
Posted on 25 Feb 2025

In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices that absorb and preserve the sample for analysis in distant laboratories. While these devices have been beneficial for monitoring medication adherence and tracking disease progression, many of the most commonly used options do not regulate the amount of blood they collect, which can lead to inaccurate results regarding a patient’s infection. Recognizing this limitation, researchers have developed a new paper-based device with wax-printed patterns that form precise channels and collection spots, ensuring a consistent volume of blood is collected every time.

A team from Tufts University School of Medicine (Medford, MA, USA) collaborated with the National Institute for Communicable Diseases (NICD, Johannesburg, South Africa) to carry out a clinical pilot involving 75 HIV-positive patients in South Africa. The NICD provided valuable real-world data, enabling Tufts researchers to compare their plasma spot cards in a clinical environment where they would be actively used. The plasma spot card developed by Tufts' research team demonstrated a more accurate measurement of a patient’s HIV infection than the widely used Roche plasma spot card (90.5% vs. 82.7%).

Published in the Proceedings of the National Academy of Sciences, the study also found that the Tufts device was better at detecting drug-resistant viral mutations (63% vs. 42%), which can inform physicians about whether to continue or change a patient's medication regimen. The researchers are now working to expand the use of this technology by forming partnerships with laboratories and researchers both in the U.S. and internationally. They are also refining the device to improve its accuracy and functionality while progressing toward its commercialization.

“We intentionally focus on developing technologies that are simple, both in construction and operation,” said Charlie Mace, an associate professor at Tufts University’s Department. “Those kinds of restrictions can make research more difficult, but ultimately we believe in that approach, because simplicity should lead to accessibility and affordability, which are both clearly needed in health care.”

Related Links:
Tufts University School of Medicine
NICD

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
C-Peptide ELISA
NovaLisa C-Peptide ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: Microscopic images showing healthy villi on the left and diseased villi on the right (Photo courtesy of Florian Jaeckle/University of Cambridge)

Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.